Boston Scientific stock fell 10% despite beating Q4 profit estimates. Investors are worried because the company expects sales to grow only 11% in 2026, a sharp drop from the 20% growth seen last year. Additionally, a large $14.5 billion deal to buy another company is making some investors nervous about future costs.